Literature DB >> 34285474

Personalized and Patient-Centered Strategies to Improve Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea.

Alexa J Watach1,2, Dennis Hwang3, Amy M Sawyer2,4.   

Abstract

Obstructive sleep apnea (OSA), a common sleep disorder characterized by repeated pauses in breathing during sleep, is effectively treated with positive airway pressure (PAP) therapy. The magnitude of improvements in daily functioning and reduced negative health risks are dependent on maintaining PAP adherence, which is a significant challenge. Evidence-based interventions to improve PAP use are not easily translated to clinical practice because they are labor-intensive and require specialty expertise. Further, to date, individualized care, inclusive of personalized medicine and patient- and person-centered care have been marginally incorporated in the field's understanding of OSA and PAP adherence. This integrative review describes current PAP adherence assessment processes, interventions to improve adherence, and outlines future opportunities to advance the field, particularly as it relates to individualizing care and the use of implementation science to apply evidence to practice.
© 2021 Watach et al.

Entities:  

Keywords:  health behavior; implementation science; patient preference; patient-centered care; precision health

Year:  2021        PMID: 34285474      PMCID: PMC8286071          DOI: 10.2147/PPA.S264927

Source DB:  PubMed          Journal:  Patient Prefer Adherence        ISSN: 1177-889X            Impact factor:   2.314


Introduction

Obstructive sleep apnea (OSA) is a common sleep disorder, characterized by repeated pauses in breathing during sleep. It is a chronic condition affecting nearly one billion adults worldwide, with nearly half requiring treatment based only on OSA severity.1 An OSA diagnosis is established using either a home sleep apnea test or in-laboratory sleep testing,2 providing an objective measure of obstructive breathing events. OSA is defined by the presence of at least five obstructive respiratory events per hour of sleep and the presence of symptoms such as daytime sleepiness, snoring, witnessed breathing interruptions, awakenings due to gasping or choking, resistant hypertension, or reduced sleep-related quality of life.2,3 Daytime sleepiness is often prioritized due to immediate safety risks, as individuals with untreated OSA are 243% more likely to have a motor vehicle accident than drivers without OSA.4–6 In addition to excessive daytime sleepiness7 and increased risk of motor vehicle accidents,5,8 untreated OSA is associated with additional adverse daytime symptoms including impaired cognitive performance,9–11 and mood disturbances.12–14 It is also associated with negative health consequences, including cardiovascular disease and hypertension,15,16 diabetes,17–19 stroke,20,21 and death.21–23 Positive airway pressure (PAP) therapy is an efficacious treatment for OSA.24 Various types of PAP devices include continuous positive airway pressure (CPAP), auto-titrating positive airway pressure (APAP), and bi-level positive airway pressure (bi-level PAP). The appropriate device type is selected based on a variety of OSA characteristics; however, the specifics of device selection are beyond the scope of this paper (see Brown & Javaheri, 2017).25 All types of PAP, however, deliver pressurized air into the airway to prevent the collapse or blockage of the airway, as caused by OSA. This requires the individual with OSA to wear a mask while asleep, during all sleep bouts, in order to prevent apneic episodes. Adherence to therapy is critical for improved patient reported outcomes including sleepiness24,26–28 and quality of life and function.24,29 Incidence of associated comorbidities such as hypertension,30–32 stroke,33,34 and insulin resistance,35,36 may also be reduced by PAP and a dose–response effect has been suggested for these improvements.27,37–39 The magnitude of these improvements and reduced risk are in part dependent on adherence to PAP. This has been a persistent obstacle for the sleep field.40 PAP treatment is behaviorally based and requires the individual with OSA to wear PAP every night. This is often a long-term commitment to treatment as no alternative OSA treatments have equivalent efficacy, particularly for moderate to severe disease.2,41 Therefore, PAP adherence and the operationalization of strategies to promote PAP adherence are critical. As both evidence-based strategies for promoting adherence and future recommendations from the sleep field are discussed herein, an integrative review approach is utilized to present the current state of the science.42 The objective of this integrative review is to describe PAP adherence assessment, adherence promotion strategies, and discuss future opportunities to advance the field, particularly as it relates to the application of personalized medicine, patient-centered care and implementation science.

Assessing PAP Adherence

Sleep medicine is at a major advantage when it comes to capabilities of tracking and monitoring treatment adherence. PAP efficacy (residual breathing events on treatment), hours of use, mask leaks, and a number of flow signals are captured and recorded by the PAP device.43 This data is downloaded from a smart card on the PAP device, or, more commonly with emerging technologies and newer devices, transferred to a cloud database via Wi-Fi or cellular connection.44 The objective, near real-time usage and effectiveness data is accessed remotely by both providers and patients. This affords patients the opportunity to track their own nightly usage on the device as well as on their smartphone, as many device manufacturers offer a companion app (eg, myAirTM [ResMed Corp., San Diego, CA, USA] or DreamMapper [Philips Respironics, Monroeville, PA, USA]). Patient engagement by self-monitoring, an influential factor for PAP adherence behavior,45–47 is presumably “standard” care with the availability of these apps, but patients must choose to utilize them. Further, remote monitoring capabilities are especially beneficial to providers and researchers, as information technology platforms are designed to risk-stratify individuals struggling to meet adherence thresholds.48,49 This has the potential to support cost-effective clinical care by enabling “management by exception” (MBE) follow-up processes. This process concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene with PAP strugglers.49,50 Other interventions to promote adherence are discussed later in this review. The ability to remotely and objectively monitor adherence is not without some negative consequence. Insurance coverage for PAP is commonly contingent upon meeting objective PAP adherence metrics set forth by the Centers for Medicare and Medicaid Services, defined as PAP usage at least 4 hours per night on at least 70% of nights within a 30-day period.51 A failure to meet this criteria within a 90-day trial period can result in loss of insurance coverage for PAP, necessitating out-of-pocket costs to continue treatment, requalification for a new PAP prescription by a healthcare provider, or treatment forfeiture. This strict and arbitrary criteria is problematic, as it results in patients not being treated at all rather than being partially treated.44 Though findings of dose–response studies are inconsistent in determining the exact amount of PAP required to reduce cardiovascular and metabolic comorbidities,52–55 evidence suggests that longer nightly use is associated with better functional outcomes such as daytime sleepiness and quality of life.27,39 A recent meta-analysis suggests that although large trials have failed to find significant associations between PAP therapy and improved cardiovascular outcomes, this is potentially a result of poor PAP use and adherence among trial participants.56 Post hoc analyses indicate that there are significant decreases in major cardiovascular events and all-cause mortality in patients wearing PAP for more than four hours per night.56 Assessment and monitoring of PAP use is but one step in the process of treating OSA with PAP. The bigger hurdle exists in the promotion, early uptake, and sustained use of PAP for individuals with OSA.

Promoting PAP Adherence

While predicting adherence to a behaviorally based treatment is complex, PAP use within the first week is robustly predictive of long-term PAP use.57–61 This importantly highlights the need for early intervention in order to potentiate adherence in the long term. Minimizing negative early experiences by addressing barriers and PAP intolerance may improve PAP acceptance and adherence, thereby avoiding abandonment or suboptimal adherence to PAP.43 Clinical guidelines suggest ensuring proper mask fit to reduce negative side effects such as air leak and discomfort and the use of humidification to reduce side effects such as dry mouth/throat or nasal congestion to improve comfort and improve adherence.2 In addition to these suggestions, there is a growing body of research investigating interventions to promote PAP adherence.24,28,62,63 These interventions have been categorized as educational, supportive, behavioral, or technological in nature, each supporting approximately one hour per night increases in PAP use within the short term (ie, 3–12 months; see Table 1).24,28,45,62 While these types of interventions are beneficial for increasing PAP use, this set of evidence has simultaneously been criticized for interventions that are not readily translatable to practice. Most interventions require substantial resources or specialized personnel not commonly available outside of a clinical trial environment and are therefore of less value for addressing PAP non-adherence clinically on a larger scale.64
Table 1

Positive Airway Pressure (PAP) Adherence Interventions

Intervention StrategyTypes of InterventionsMean Difference (MD) in PAP Use, by Meta-AnalysisEndpoints
EducationalWritten materials, watching a video, face-to-face didactic sessionsMD 0.55 hrs/night higher (95% CI=0.04, 1.06)638 participants (7 RCTs)241 mo–1 yr24
MD 0.85 hrs/night higher (95% CI=0.32, 1.39)1128 participants (10 RCTs)283 mos28
BehavioralMotivational enhancement, cognitive behavioral therapy, stage matched interventionMD 1.15 hrs/night higher (95% CI= 0.27, 2.04)517 participants (6 RCTs)241 mo–1 yr24
MD 1.31 hrs/night higher (95% CI=0.95, 1.66)578 participants (8 RCTs)283 mos28
SupportiveTroubleshooting/ practical support (home visits, phone calls from medical or non-medical personnel, automated phone calls, and inquiries via computer)MD 0.66 hrs/night higher (95% CI=0.19, 1.13)670 participants (9 RCTs)241 mo–1 yr24
MD 0.70 hrs/night higher (95% CI=0.36, 1.05)1426 participants (13 RCTs)283 mos28
TechnologicalIntervention delivered via telephone calls, telemedicine (eg, videoconferencing), websites, smartphone applications, textingTelemonitoringMD 0.54 hrs/night (95% CI=0.29, 0.79)5429 participants (18 RCTs)451 mo–6 mos45
MD 0.98 hrs/night (95% CI=0.53, 1.42)498 participants (5 RCTs)241 mo–1 yr24

Note: hrs, hours; mo(s), month(s); RCT, randomized controlled trial; yr, year.

Positive Airway Pressure (PAP) Adherence Interventions Note: hrs, hours; mo(s), month(s); RCT, randomized controlled trial; yr, year. Many factors interact to predict PAP adherence,26,63,65 and many tested interventions have been designed and developed based on factors known to influence adherence such as experienced side effects (eg, skin irritation, dryness in the nose or mouth, and abdominal bloating)65 and psychosocial factors (eg, skills at coping with challenging situations, mental health, self-efficacy, and social support).26,63,65,66 However, some risk factors for nonadherence are non-modifiable, such as patient characteristics (eg, age, race, socioeconomic status),26,63,66 and disease characteristics (eg, symptom severity, OSA severity, mask type).63,67 To date, individualized care, inclusive of personalized medicine and patient- and person-centered care, has only marginally made its way into developing a deeper understanding of OSA and PAP adherence.44,48,68 Rather than pursuing a “one size fits all” approach to improving PAP adherence, further information on OSA risks, varied characteristics of OSA presentation, and patient preference could markedly enhance the availability of more individualized approaches that may be more promising with regard to effectiveness and scalability.69

Individualized Care

Personalized medicine and patient- and person-centered care are three care concepts seeking a similar goal—individualized health care for each patient.70–72 These individualized approaches place patients at the pinnacle of care, but differ in their core components and defining characteristics. Personalized medicine stems from a more biomedically based framework; determining who is at risk for disease, preventing disease, personalizing treatment, and involving patient participation. The goal of patient-centered care is focused on meeting patient’s needs by understanding patient values and preferences and promoting patient engagement and shared decision-making with an overall focus on functional life for the patient.70–72 Person-centered care broadens and extends the goals of patient-centered care to consider the whole life of the patient, beyond the impact of disease.70–72 See Table 2 for brief examples of how each of these individualized approaches to health care can be operationalized in OSA/PAP care. Implications for the use of personalized medicine and patient-centered care in sleep medicine have been previously published.44,48,68,69,73,74 This review brings into focus the opportunity to apply personalized medicine and patient-centered care to the promotion of PAP adherence.
Table 2

Individualized Health Care Approaches and Applications

ApproachDefinitionExample for OSA/PAP Care
Individualized healthcarePersonalized medicineUsing an individual’s clinical history and biological characteristics to tailor therapies to that person.68Tailoring care/treatment by: ● Treating insomnia (for a patient with an insomnia phenotype of OSA).75–77 ● Examining clinical history for cardiovascular disease or poorly managed hypertension, despite antihypertensive regimen.
Patient-centered careGenerally, refers to communication and interactions in clinical visits. Centers around the management of disease with patients’ preferences prioritized.72Prioritizing the patient by: ● Using a shared decision-making tool and varying treatment plan based on patient preferences, such as negotiating hours/days or days/week of PAP use, based on work or weekend schedule ● Discussing a treatment plan that “works for them”, based on sleep habits or preferred sleeping environment ● Using visit satisfaction surveys ● Personalizing patient education based on individual risks (eg, multiple chronic conditions)
Person-centered careGenerally, views diseases as interrelated phenomena and considers the evolution of individuals experienced health problems and diseases over time. A focus on individuals right to self-determination and ideally involves a long-standing relationship between provider and patient for a more holistic view.72Treating the whole person by: ● Creating care teams so patients regularly interact with the same providers and staff ● Developing case management approaches wherein a point of contact is assigned and that contact works across interdisciplinary teams (eg, primary care, sleep, cardiology) to coordinate care for the individual
Individualized Health Care Approaches and Applications

Personalized Medicine

Personalized medicine approaches consider individual differences that are influential in the diagnosis and treatment of disease.68 “P4 medicine” is an approach to medicine that includes (1) predicting who will develop disease and comorbidities, (2) preventing disease rather than reacting, (3) personalizing diagnosis and treatment, and (4) patient participation in their own care.48,68,78,79 With regard to PAP adherence, personalization and patient participation are of particular relevance in this P4 medicine model. OSA has historically been defined and treated according to disease severity based on the apnea hypopnea index.68 However, a shift in this approach may be necessary to promote adherence, as clinical subgroups of patients with OSA present with varied clinical phenotypes.68 Three distinct subgroups emerged to date, include (1) patients with insomnia complaints, (2) largely asymptomatic patients with cardiovascular comorbidities, and (3) excessive daytime sleepiness patients.48,80 Phenotypic presentations may result in patients having varied individual needs, preferences, and values that have important therapeutic implications in treatment decision-making. This variance may require different and individualized approaches to promoting adherence to therapy. Not all patients with OSA will develop cardiovascular complications, and not all patients with OSA will be sleepy; this may potentiate varied intrinsic motivation by patients to treat their OSA and adhere to PAP therapy. For example, adhering to therapy may be obvious to an individual who experiences a dramatic improvement in their daytime sleepiness, thus serving as a motivating factor for continued use of PAP. However, patients that are asymptomatic but are “invisibly” developing cardiovascular risks may not be similarly motivated to use PAP therapy as there is no perceived immediate benefit or reward. In this case, it is imperative to understand what will motivate asymptomatic patients to adhere to therapy and how best to leverage that motivation to support adherence. Individuals with an insomnia phenotype of OSA may experience worsened sleep quality as they adjust to sleeping with a PAP machine. Managing adherence in this group may require a substantially different approach than one used for individuals with a different clinical phenotype of OSA. “Lower and slower” adherence thresholds may be better aligned with the individual nature of the insomnia phenotype along with targeted cognitive behavioral intervention approaches. The identification of these clinical phenotypes is an important discovery to move the field of sleep medicine toward a personalized approach to OSA care, as patient-specific needs and patient-specific benefits of PAP therapy are identified. An additional component of personalized medicine is patient participation. This participatory approach to medicine takes the patient from a passive receiver of care to actively managing and engaging in their own health and healthcare-related decisions.68,78 Patient engagement studies in other chronic diseases have highlighted improved clinical outcomes, increased engagement in healthy behaviors, reduced progression in disease burden, greater use of preventive healthcare, and reduced costs.81,82 Efforts to engage patients can be maximined with the use of new technologies for health (eg, eHealth and telehealth resources).83 PAP management is particularly well suited for engaging patients in their own health care. As previously highlighted, remote monitoring capabilities and apps support patients to monitor their own nightly PAP use and thus create accountability and awareness.

Patient-Centered Care to Enhance Patient Preference

A patient-centered care approach should be prioritized in order to enhance PAP acceptance and encourage PAP use.44,73 This is especially true as OSA affects individuals with varied needs, values and preferences. Men are two times as likely as women to have OSA,84 while women are less likely to adhere to PAP than men.85 Black, Hispanic, and Latino individuals are disproportionately affected by OSA,40,84,86,87 yet are less likely to be diagnosed and treated.88,89 Individuals from disadvantaged communities and of lower socioeconomic status are also at higher risk for OSA but less likely to adhere to PAP therapy.88,90,91 A “one size fits all” approach to managing PAP adherence is bound to fail when addressing a diverse OSA population. To individualize care and promote patient preference, patient-centered PAP care should include the following: (1) assessing and enhancing patient readiness, beliefs, and expectations about OSA and PAP, (2) employing health-literacy aligned patient education that is accessible to the diverse OSA population, (3) understanding patient values and preferences and collaborating on a plan for change (ie, shared decision-making), and (4) promoting patient engagement.

Assess and Enhance Patient Readiness, Beliefs, and Expectations

PAP therapy requires substantial behavior change. A new nightly routine must be adopted; daily, weekly, and monthly equipment maintenance and cleaning schedule must be established; and, additional clinical appointments for follow-up care are necessary. Patients feel most ready to adopt PAP when they perceive that PAP therapy is important and that they possess the skills to manage their care effectively.73 Understanding patients’ beliefs and expectations about PAP, as well as dismantling or enhancing preconceived notions and expectations, is critically important, as these factors may influence their decision to use PAP.67,92,93 Patient readiness and belief in their own abilities to use PAP can be clinically evaluated by one question: “On a scale of 1–10, how confident are you in your ability to use PAP from now until the next time we meet?”73 If this number is low, asking “What might make that number higher?” is a good strategy to identify patient-specific needs to increase confidence and perceived self-efficacy,73 as increased self-efficacy predicts improvements in PAP use.94,95 To improve confidence, increase self-efficacy, and address patient-specific needs, a variety of strategies can be used, including motivational enhancement therapy,96 teach-back methods,97 and allowing time for patients to “buy in” to therapy with gradual use/practice that increases their confidence and garners commitment.67 Promoting a discussion that leads to the identification of patient-specific beliefs, expectations, and confidence with PAP therapy can lead to an individualized treatment plan that is feasible and agreeable to the patient. A critical next step in following a patient-centered care model is to use these identified beliefs, expectations, and confidence in abilities to provide education that is tailored to meet and address personal needs.

Enhancing Patient Education

Risk perception is based on one’s beliefs, expectations, knowledge and awareness of a condition.98,99 This makes it critically important to dispel inaccurate notions and replace misperceptions with truths because misperceptions of health information can influence health-related decision-making. Misinformation can also lead to confusion, minimization of risk, frustration, care avoidance, nonadherence, and treatment abandonment.100 Standard education about OSA and PAP that is provided to patients commonly includes face-to-face communication with a provider, a brochure or handout, and occasionally educational videos often developed by medical device companies or professional practice organizations. Problematically, these common OSA and PAP education materials have high health literacy demands and provider communication is often too complex.101,102 Further, individuals that are at increased risk for OSA and PAP non-adherence, such as those of low socioeconomic status88,90,91 and African American, black, Hispanic, and Latino populations,40,63,84,86–88,103 are also populations that are more likely to have limited health literacy, which creates and extends inequities in care.104 Health literacy-aligned approaches to patient education are needed to empower patients to make informed decisions about their care and to ensure health information is accessible and usable by all OSA patients. In addition to health literacy concerns related to established education practices, the current approach to patient education takes a “one size fits all” approach—everyone receives the same education on what OSA is, what PAP is, and how PAP can improve their health. In contrast, a patient-centered approach to educating patients will use dialogue about beliefs, expectations and readiness for change to guide and shape the education provided. For example, a patient expresses that they are concerned about OSA and their increased risk for diabetes because “everyone in my family is diabetic.” In this case, it may be important to focus education on the benefits of OSA treatment and diabetes risk that best aligns with the individual’s motivation to use PAP. Another approach uses dialogue that first addresses patient concerns to promote a more productive and personalized education session. For example, if a patient is concerned that starting PAP therapy will increase their electric bill and jeopardize their finances, these concerns may distract the patient from absorbing additional important education. A patient-centered interaction that first explicitly addresses concerns and/or fears may result in a more positive, patient-centered experience and translate to enhanced use of PAP.93 Patient-centered dialogue that explicitly incorporates and prioritizes patient beliefs, expectations, and readiness will meet patients’ needs and is consistent with personalized education by being better aligned with the individual patient. As engaged participants in their own care, considerations should be given to patient preferences and autonomy in decisions to pursue treatment.

Patient Values, Preferences and Collaboration in a Plan for Change

Perhaps the most foundational component of patient-centered care is respect for patients’ values and preferences for their own health priorities. Patient-provider communication can be challenging. It is even more challenging in the context of specialty sleep care when patients meet a sleep provider for the first time and receive a diagnosis and treatment options in a single encounter. By design, this commonplace practice approach provides little opportunity to discuss patients’ preferences and establish care goals with the provider.105 Adherence “goals” are consistently pre-determined by insurance requirements,51 and patient preference in the context of treatment decisions is largely limited to selecting a PAP mask that “feels best”.67 Yet, the mask-fitting session does provide an opportunity to employ patient-centered principles by promoting patient engagement, providing education about advantages and disadvantages of varied mask types, ensuring understanding, and addressing individual questions.67 To improve the mask-fitting experience, three-dimensional face scanning is an innovative approach to individualize PAP care.106 This technology provides vital information on which masks may be best for a patient according to the patients’ facial anatomy.106 By reducing the complexity of mask selection by patients, novice to the treatment, patient decision-making is supported.67 Shared decision-making supports personalized PAP care and improves adherence to OSA treatment.107 As previously noted, adherence goals are often pre-determined; collaborating on how best to achieve that goal is an opportunity to use shared decision-making strategies. This two-way process of information sharing and mutual goal setting can be enhanced with the use of decision aids, tools that present options and help patients clarify their values.108 Decision aids can reduce decisional conflict related to feeling uninformed or unclear about treatment options and how the options align or misalign with their own values.108,109 OSA decision aides have proven beneficial for increasing disease-specific knowledge, reducing decisional conflict, are perceived as useful by patients, and increase preparedness for decision-making.110,111 Decision aids to date have rarely been developed with lower literacy populations in mind.112,113 Importantly, health literacy should also be considered during the development of decision aids, as a tool that cannot be readily understood or used is of little value. A collaborative approach to care is associated with more self-management, care that is aligned with values, and increased patient satisfaction.114 Providers’ awareness of using patient-centered communication during PAP initiation can improve the care provided.115 By understanding patients’ beliefs and expectations, acknowledging and incorporating patient values and preferences, and collaborating on a plan for care, patients become more empowered to self-manage and act as “active care participants” rather than as “passive care recipients.”67 Promoting patient engagement is another patient-centered approach to care and also meets the needs of personalized medicine by promoting patient participation. Given objective measures of PAP use, and near real-time translation of this data, self-monitoring and telemonitoring is an opportunity for patients to further engage in their care.

Patient Engagement and Self-Monitoring

Research on improving PAP adherence and advancements in device technology have continued to evolve. Patients are increasingly interested in engaging in their own health management, as evidenced by the rapid growth in health apps and wearable devices, independently seeking medical information online, and the increased use of patient portals for electronic medical records.44,116 As previously noted, patient-facing apps are available from PAP device companies, affording patients the opportunity to self-monitor their nightly PAP use.117 Monitoring of one’s own PAP use is beneficial for increasing PAP adherence,45–47,118 however, patients must choose to actively engage with the apps to acquire this benefit. Research has demonstrated that interests and abilities to engage in patient portals are influenced by personal factors such as age, ethnicity, education level, health literacy, and health status.119 This further highlights the need for a variety of strategies for engagement to optimize individualized care approaches.119 Telemonitoring, including the use of automated messaging, coaching, reinforcement emails/texts/calls/patient portal messages, education, and videoconferencing, presents additional opportunity to employ patient engagement strategies to improve PAP use.49,64,117,120–122 Early engagement by telemonitoring and subsequent outreach can prevent PAP nonadherence.45 Trials have demonstrated telemonitoring encounters to be successful in improving PAP use49,122–124 and reducing the rate of long-term therapy termination.125 Though remote telemonitoring is standard care for PAP management, long-term telemonitoring of large volumes of patients and nightly data from entire clinics is often not sustainable.117 This clinical approach to telemonitoring relies on patients to engage, self-monitor and reach out to healthcare providers with problems. This last step may occur late in the cycle of behavior change126,127 and lead to treatment failure.59,128,129 To improve monitoring capacities, reduce staff burden, and extend telemonitoring beyond the typical 90-day window, the use of software and technology platforms that apply artificial intelligence technologies are warranted. Embedded algorithms and application of decision rules to identify poor adherence and automate alert messages may provide a feasible solution for managing large amounts of PAP data.117 Future studies are needed to determine the effects of continued, long-term engagement of patients via PAP telemonitoring, especially in context of clinical trials wherein adherence must be maintained in order to assess PAP effectiveness on various clinical endpoints/outcomes such as cardiovascular and metabolic risks.64 Clear OSA telehealth algorithms and pathways can support more individualized care by applying varied telehealth engagement strategies to specific populations. For example, as previously noted, varied OSA phenotypes or patient characteristics may influence responsiveness to telemonitoring engagement strategies or intrinsic motivation to self-monitor. These individualized differences are an important consideration for determining who will engage, and how best to target varied populations. This does not necessarily involve “reinventing the wheel”, per se, as telehealth/telemonitoring technologies provide the opportunity to deliver improved OSA care by more widely and efficiently distributing evidence-based interventions (EBIs) for PAP adherence, including behavioral, educational, and supportive interventions.130 There is, however, opportunity to examine who responds best to what type of intervention, while simultaneously examining the most effective way to implement the EBI to practice.

Implementation Science as a Way Forward

Practical implementation of EBIs into practice requires an understanding of the local context in which it will be applied. As previously noted, interventions developed to date are not readily translatable to clinical practice. While there is a growing set of evidence for interventions that improve PAP adherence, very few trials have sought to understand how interventions will function outside of a clinical trial environment, nor have they employed patient-centered approaches. Future patient-centered approaches should include engaging patient stakeholders at the outset of intervention development131 or, with testing interventions that are specifically tailored to meet individual’s needs.92 Studies that embed EBIs that are effective at improving PAP adherence for a wide variety of patients with varied needs are needed to inform clinical practice and move away from a “one size fits all” approach to managing PAP adherence.69 An implementation gap separates the scientific knowledge we have about PAP adherence and the implementation of such knowledge into effective interventions or clinical care.130 Implementation science methodologies and study designs provide a real opportunity to translate EBIs faster while also focusing on creating interventions that are acceptable, feasible, cost effective, and sustainable. Implementation science is the scientific study of methods to promote the systematic uptake of research findings and other evidence-based practices and interventions into routine practice, and, hence, to improve the quality and effectiveness of health services.132 In other words, implementation science research evaluates the process of implementing an evidence-based practice or EBI and how to do so most effectively. Implementation studies typically employ mixed quantitative-qualitative designs to identify specific factors that impact adoption or uptake across patient, provider, and organizational levels.132 The ability to systematically and strategically embed an EBI, while simultaneously collecting feedback from the patient makes implementation science a vehicle to incorporate patient-preferred, effective interventions for PAP adherence. Further, implementation science focuses on facilitators and barriers to adoption of an EBI, measuring the ways people engage and respond to an intervention. This includes gaining an understanding of the context in which the intervention is to be applied at the patient, provider, and organizational level. In its most true fashion, implementation science research involves employing EBIs in “real world settings”, testing various strategies to promote the adoption and uptake of an EBI in a given setting. However, implementation science research priorities can also be applied in controlled implementation trials to examine barriers and facilitators of intervention adoption to prepare for scaling, larger trials, and wider dissemination. Many PAP trials to date have included interventions that are not readily translatable to practice.64 By adapting these interventions so they are adoptable and manageable in practice settings, the effectiveness and clinical utility of these PAP adherence interventions can be tested simultaneously, leading to a more efficient research process. A dual-focus approach to research (ie, assessing both effectiveness of implementation and the health impact of an EBI), coined hybrid implementation-effectiveness design, has the potential to identify effective interventions, while concurrently studying implementation strategies to promote uptake of the EBI.132,133 PAP adherence trials that use implementation science designs will better clarify effectiveness of various PAP interventions in real-world settings as well as determine effective implementation strategies for such interventions.130 PAP adherence interventions tested to date are mixed component approaches with a single predominant component (eg, educational plus supportive interventions; supportive plus behavioral interventions).28 Identifying the core versus adaptable components of interventions using implementation methods will aid in determining the most effective interventions. Additionally, implementation trials present the opportunity to test implementation strategies to optimize the uptake of interventions. Further, with the growth of personalized medicine and phenotyping of OSA, the field is well positioned to examine who responds best to what type of intervention using an implementation science approach. This can also incorporate patient preference, either directly by measuring acceptability and engaging stakeholders to understand preferences, barriers, and the overall context in which interventions are applied, or indirectly by examining reasons for failed adoption. The sleep field currently has an abundance of early-stage efficacy research, but less later-stage implementation research to support practice translation. Recognizing this need, both the American Thoracic Society (ATS) and the Sleep Research Society (SRS) organized workshops to discuss how implementation science can be applied and adopted in sleep medicine and have released research statements.130,134 ATS and SRS have recognized this opportunity for growth in the sleep field, and with the support of other organizations and societies, implementation science in sleep medicine is a strategic and warranted approach to promote PAP adherence and best PAP care. We can move the field forward by linking sleep researchers, implementation scientists, industry and insurance partners, front-line clinicians, and patients to problem solve and propose feasible interventions to promote PAP adherence. Although efficacy trials are critically important, the field needs to utilize existing EBIs, adapt them to be practical and translatable with the help of stakeholder engagement, and deploy and test their implementation. Conducting such implementation trials that simultaneously evaluate efficacy, effectiveness, and implementation will begin to shorten the persistent 17-year gap of research to practice translation that plagues the field.

Conclusion

Individualized care, whether by a personalized medicine or patient-centered approach, places the patient and their individual characteristics, needs and preferences as a top priority. An individualized care approach with the patient at the pinnacle has the opportunity to improve patient-preferred outcomes, PAP care, and PAP adherence. This review highlights the work that is taking place to move toward individualized care in sleep medicine. Many effective PAP adherence interventions developed to date are in need to refinement in order to 1) be individualized to patients’ needs whether biological (ie, OSA phenotype) or psychosocial (ie, patient preference), and 2) to be readily applied to practice and tested on a clinical scale. This intervention development and refinement should consider leveraging previous qualitative research findings to encourage interventions that are designed based on patient identified needs.93,135–138 Further, prioritizing patient preference, engaging patient stakeholders, and collecting patient-centered outcomes should continue to be pursued to better understanding PAP adherence. The Patient-Centered Outcomes Research Institute (PCORI) has funded work in this area, including the Sleep Apnea Patient-Centered Outcomes Network (SAPCON), a collaborative group of patients, researchers and clinicians focused on generating patient-centered research,69 peer support programs to improve treatment satisfaction for adults with OSA,131 and engagement of patient, provider, professional organization, and medical equipment providers to help plan and design studies139 and understand PAP adherence barriers.140 Lastly, to begin to test PAP adherence interventions on a broader and more diverse scale, whether it be patient diversity, geographic diversity, or diversity related to clinic resources (ie, a large academic institution versus rural sleep clinic), sleep researchers should seek to collaborate to gain a better understanding of how EBIs function in various OSA populations and within varied settings. This endeavor is far too large to accomplish alone, but through strong scientific collaborations, PAP care can be optimized, patient care improved, and perhaps most importantly, patient health outcomes improved. Sleep medicine is on a promising path to develop individualized approaches to PAP care through the continued research on personalized medicine and patient-centered care, and implementation science can provide a critical vehicle to more rapidly move EBIs to practice for the benefit of all patients.
  131 in total

1.  Differences in perceptions of the diagnosis and treatment of obstructive sleep apnea and continuous positive airway pressure therapy among adherers and nonadherers.

Authors:  Amy M Sawyer; Janet A Deatrick; Samuel T Kuna; Terri E Weaver
Journal:  Qual Health Res       Date:  2010-03-30

Review 2.  Patient Partnerships Transforming Sleep Medicine Research and Clinical Care: Perspectives from the Sleep Apnea Patient-Centered Outcomes Network.

Authors:  Susan Redline; Si Baker-Goodwin; Jessie P Bakker; Matthew Epstein; Sherry Hanes; Mark Hanson; Zinta Harrington; James C Johnston; Vishesh K Kapur; David Keepnews; Emily Kontos; Andy Lowe; Judith Owens; Kathy Page; Nancy Rothstein
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

3.  Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2019-02-15       Impact factor: 4.062

4.  Meta-analyses of the Association of Sleep Apnea with Insulin Resistance, and the Effects of CPAP on HOMA-IR, Adiponectin, and Visceral Adipose Fat.

Authors:  Imran H Iftikhar; Camilla M Hoyos; Craig L Phillips; Ulysses J Magalang
Journal:  J Clin Sleep Med       Date:  2015-04-15       Impact factor: 4.062

5.  Sleep-disordered breathing and insulin resistance in middle-aged and overweight men.

Authors:  Naresh M Punjabi; John D Sorkin; Leslie I Katzel; Andrew P Goldberg; Alan R Schwartz; Philip L Smith
Journal:  Am J Respir Crit Care Med       Date:  2002-03-01       Impact factor: 21.405

6.  Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study.

Authors:  Naresh M Punjabi; Eyal Shahar; Susan Redline; Daniel J Gottlieb; Rachel Givelber; Helaine E Resnick
Journal:  Am J Epidemiol       Date:  2004-09-15       Impact factor: 4.897

7.  Self-efficacy in sleep apnea: instrument development and patient perceptions of obstructive sleep apnea risk, treatment benefit, and volition to use continuous positive airway pressure.

Authors:  Terri E Weaver; Greg Maislin; David F Dinges; Joel Younger; Charles Cantor; Susan McCloskey; Allan I Pack
Journal:  Sleep       Date:  2003-09       Impact factor: 5.849

Review 8.  Mask interface for continuous positive airway pressure therapy: selection and design considerations.

Authors:  Zhichao Ma; Michael Drinnan; Philip Hyde; Javier Munguia
Journal:  Expert Rev Med Devices       Date:  2018-10-01       Impact factor: 3.166

9.  Communication during the initial visit to a CPAP clinic Practitioners' experiences of facilitators and barriers when talking to patients with obstructive sleep apnea.

Authors:  Anders Broström; Bengt Fridlund; Bjöörn Fossum; Amir Pakpour; Per Nilsen; Martin Ulander
Journal:  J Sleep Res       Date:  2020-12-13       Impact factor: 3.981

10.  Efficacy of a patient decision aid for improving person-centered decision-making by older adults with obstructive sleep apnea.

Authors:  Constance H Fung; Jennifer L Martin; Li-Jung Liang; Ron D Hays; Nananda Col; Emily S Patterson; Karen Josephson; Michael N Mitchell; Maria C Sanchez; Ravi Aysola; Yeonsu Song; Joseph M Dzierzewski; David Huang; Michelle Zeidler; Cathy Alessi
Journal:  J Clin Sleep Med       Date:  2021-02-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.